title: Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
abstract: ClinicalTrials.gov: NCT00427934.
journal: Arthritis Research & Therapy